Your search for comorbidities returned 10 results

Researchers analyzed data taken from EHR insurance claims of 149,654 patients aged 25 years and older between January 2016 and September 2020.

The primary objective of this study was to assess whether the potential independent effects of secondary hyperparathyroidism on the risk for CKD progression and cardiovascular event incidence in CKD patients act as effect modifiers.

Study finds that the use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index.

The effects of hybrid comprehensive telerehabilitation compared with usual care were analyzed in a cohort of patients with HFrEF.

A systematic review and meta-analysis was conducted to look at the effects of body mass index on atrial fibrillation‐related outcomes in anticoagulated patients.

Significant improvements to the management of metabolic syndrome after liver transplantation must be made to reduce the risk for CV events and mortality.

Investigators evaluated various drug therapies for dyslipidemia in elderly patients.

Glucose-lowering medications and high-intensity statins are not being used sufficiently among high-risk individuals with atherosclerotic cardiovascular disease and diabetes.

Dr Christine Lee discusses her work on how to capture the patient’s voice by using multiple data sources, such as unstructured FDA archival data and social media.

Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.